Planegg – Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming investor and scientific conferences:
ISMB 2018 – 26th Conference on Intelligent Systems for Molecular Biology
Date: 6 – 10 Juli 2018
Location: Chicago, USA
Oppenheimer & Co. Boston Oncology Insight Summit
Date: 10 – 11 July 2018
Location: Boston, USA
Immuno-Oncology Summit, Boston
Date: 30 – 31 August 2018
Location: Boston, USA
Prof. Dolores Schendel, CEO and CSO of Medigene AG, is invited to hold a company presentation.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit https://medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,
email: investor@medigene.com